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USD868.3 for EAC and RAC groups respectively. The overall
cost/patient for H. pylori eradication was USD849 and USD
847.3 for EAC and RAC groups respectively. No signiﬁcant
adverse effects were experienced by patients in either group and
hence cost incurred in this area was minimal. CONCLUSION:
Esomeprazole and rabeprazole triple therapies appear to have
similar effectiveness in H. pylori eradication in patients with
non-ulcer dyspepsia. Rabeprazole triple therapy may have cost
savings when the whole population is considered.
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OBJECTIVE: Different treatments are available for Atopic Der-
matitis care. The preferences of patients should be taken into
consideration in the development of treatment strategies. The
aim of this study is to establish patients’ preferences and their
willingness-to-pay (WTP) on different AD treatment options.
METHODS: The CODA study was a naturalistic, multicentre,
longitudinal ambispective (retro-prospective), prevalence based
Cost-of-Illness study. Data on patients with moderate or severe
AD enrolled during ﬂare-up were collected. A discrete-choice-
experiment (DCE) was applied to enrolled patients. The follow-
ing attributes were considered to be important after interviewing
20 patients: pharmaceutical formulation (water-based cream vs
oil-based cream), the delay of The rapeutic response (4hours vs.
24hours vs. 48 hours), duration of therapeutic response (1 week
vs. 4 weeks vs. 8 weeks), long-term side effects and local side
effects (possible vs no). In order to estimate the WTP we added
the out-of-pocket cost of treatment (€0 vs. €50 vs. €100/month).
RESULTS: One-hundred-and-one of the 104 enrolled patients
(males 53.8%, mean age = 32.9 ± 11.8) ﬁlled in the DCE ques-
tionnaire. All attributes, excluding pharmaceutical formulation,
were relevant in patients’ choice (P < 0.001). Since the attribute
“cost” is determinant in the choice, a monetary value can be
assigned to each other relevant attribute. The conditional-probit-
model demonstrated that patients are willing-to-pay per month:
€104 for a “8 weeks therapeutic response” compared with 1
week; €47 for a treatment with “no local side effects”; €45 for
a treatment with “no long term side effects”; €21 for a “thera-
peutic response delay” of just one day. CONCLUSIONS: To our
knowledge, our study is the ﬁrst to elicit patients’ preferences
and their WTP for AD treatment. This information can guide
clinicians and decision makers to plan optimal health care.
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OBJECTIVES: To test whether the health of the mothers is
affected by the presence of a disabled or chronically-ill child.
METHODS: Using the National Longitudinal Survey of Chil-
dren and Youth (1994–2000), a nationally representative house-
hold survey in Canada, ordered Probit analysis was used to test
the effect of the presence of a disabled child on self-reported
health, controlling for other factors. Firstly, we modeled the
health effect of a disabled child in the house currently. Secondly,
utilizing the longitudinal aspect of the data, we modeled the
effect of the presence of a disabled child: a) currently only; 
b) previous years only; and c) both currently and previously.
Married and lone mothers are analyzed separately for children
aged 6–15 years of age in 2000 for a sample size of 5217 and
1177 for married and lone mothers, respectively. Bootstrap stan-
dard errors were calculated to account for multi-staged, non-
random survey design. To cope with causal inference issues we:
1) control for previous health status, and 2) test results using
propensity score matching (PSM). RESULTS: Evaluating at the
sample means, model 1 indicates a shift down in the health dis-
tribution for mothers with disabled children. There is a lower
probability of excellent health of 10[8.8–11.2] percentage points
for married mothers with a disabled child compared to house-
holds with no disabled children. Lone mothers show a difference
of 9[7–11] percentage points although health for lone mothers
is lower in general compared to married mothers. Model 2 shows
the strongest association for those households with a disabled
child both currently and in the past. PSM analysis conﬁrms our
results. CONCLUSIONS: The presence of a disabled or chroni-
cally-ill child has a statistically signiﬁcant effect on the health of
mothers. Consequences for maternal health are larger in the
long-run, if the child’s condition persists.
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OBJECTIVE: Validating a German child-friendly version of 
the EuroQol (EQ-5D) in different patient samples. METHODS:
After the translation from the original English version and
pretesting in cognitive interviews with native speakers of the
target language, the questionnaire was tested in two patient
groups (obesity and CF) and a sample of healthy children
between the ages of 8 and 16. For the validation three validated
instruments which measure hrQol in children and adolescents
were utilized (KINDL, KIDSCREEN and ChildDynHA). T-Tests
were conducted to audit potential differences in the EQ-5D
scores depending on age and sex of the children. Descriptive sta-
tistics were used to summarize EQ-5D scores as well as scores
of the additional instruments. RESULTS: The correlation
between the EQ-5D and the other instruments was quite high
(0.46–0.61). The highest correlation was found in the mobility
dimension. The CF groups shows the highest rates of reported
problems (42%), the rates of children who report no poblems
are quite similar for the obese and the healthy children (25 versus
27). CONLUSIONS: This pilot study of the questionaire showed
that the German child-friendly version of the EQ-5D is a valid
and feasible instrument to measure hrQol.
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In line with international trends, methylphenidate prescriptions
in Germany have been growing 20-fold over the last decade. This
has contributed to concern about potentially inappropriate and
excessive psychostimulant treatment for youths. OBJECTIVE:
To clarify methylphenidate prescriptions for children and ado-
